Abnormalities of the extracellular degradation of collagen type I in essential hypertension

Circulation

Volumn 98, Issue 6, 1998, Pages 535-540

  Laviades, Concepción ^a   Varo, Nerea ^c   Fernández, Javier ^c   Mayor, Gaspar ^b   Gil, María J ^c   Monreal, Ignacio ^c   Díez, Javier ^d  

^a HOSPITAL SAN JORGE   (Spain)

^b San Jorge General Hospital   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Collagen; Hypertension; Metalloproteinases; Peptides; Remodeling

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

EID: 0032508355     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.6.535     Document Type: Article

References (34)

1. Jalil JE, Doering CW, Janicki JS, Pick R, Clark WA, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989;64:1041-1050.
2. Bashey RI, Cox R, McCann J. Jimenez SA. Changes in collagen biosynthesis types, and mechanics of aorta in hypertensive rats. J Lab Clin Med. 1989;113:604-611.
3. Weber KT, Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep. 1991;12:61-69.
4. Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, Zhou G. Myocardial fibrosis in hypertensive heart disease: an overview of polential regulatory mechanisms. Eur Heart J. 1995;16(suppl C):24-28.
5. Díez J, Panizo A, Gil MJ, Monreal I, Hernández M, Pardo Mindán J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation. 1996;93: 1026-1032.
6. Díez J, Hernández M. Is the extracellular degradation of collagen type I fibers depressed in spontaneously hypertensive rats with myocardial fibrosis? Circulation. 1996;94:2998. Letter.
7. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-1456.
8. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;131:2145-2154.
9. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987;252:C1-C9.
10. Denhardt DT, Feng B. Edwards DR. Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993;59:329-341.
11. Alexander CM, Werb Z. Extracellular matrix degradation. In: Hay ED. ed. Cell Biology of Extracellular Matrix. New York, NY: Plenum Press; 1991:235-275.
12. Montaño M, Ramos C, González G, Vadillo F, Pardo A. Selmán M. Lung collagenase inhibitors and spontaneous latent collagenase activity in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Chest 1989; 96:1115-1119.
13. Li J, Rosman AS, Leo MA, Nagai Y, Lieber CS. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology. 1994;19:1418-1423.
14. World Health Organization. Hypertension Control. Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1996.
15. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
16. Ganau A, Devereux RB, Roman MJ, De Simone G. Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
17. Quinones MA, Pickering E, Alexander JK. Percentage of shortening of the echocardiographic left ventricular dimension: its use in determining ejection fraction and stroke volume. Chest. 1978;74:59-65.
18. Nishimura RA. Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current application of Doppler echocardiography, II: clinical studies. Mayo Clin Proc. 1989;64:181-204.
19. Risteli J, Elomaa I. Niemi S. Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993:39:635-640.
20. Zhang J, Fujimoto N. Iwata K. Sakai T, Okada Y. Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta. 1993;219:1-14.
21. Kodama S. Iwata K. Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis serum and plasma. J Immunol Methods. 1990;127:103-108.
22. Clark IM, Wright JK, Cawston TE, Hazleman BL. Polyclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure TIMP-collagenase complex. Matrix. 1992;12:108-115.
23. Laurent GJ, Bates PC, Sparrow MC, Milward DJ. Muscle protein turnover in the adult fowl, III: collagen content and turnover in cardiac and skeletal muscles in the adult fowl (Gallus domesticus) and the changes during stretch-induced growth. Biochem J. 1978;176:419-427.
24. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
25. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
26. Edwards DR, Murphy G, Reynolds JJ, Whithman SE, Docherty AJ, Angel P, Heath JK. TGF-β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987;6:1899-1904.
27. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD. Cuccurullo F, Colletta G. Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 1997;30(pt 1):134-139.
28. Brilla CG, Moderer S. Salge U, Heidmann HH. Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophie cardiomyopathy. Circulation. 1994; 90(suppl I):I-264. Abstract.
29. Brilla CG, Matsubara L. Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension. 1996;28:269-275.
30. 1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
31. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1419-1424.
32. Wolf G. Müller E, Stahl RAK, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor β. J Clin Invest. 1993;92: 1366-1372.
33. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23(pt 2):869-877.
34. 2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D-13D.